Stammdaten
Maze Therapeutics, Inc., ein Biopharmaunternehmen im klinischen Stadium, entwickelt Kleinmolekül-Präzisionsmedikamente zur Behandlung von Nieren-, Herz-Kreislauf- und damit verbundenen Stoffwechselerkrankungen sowie Adipositas in den Vereinigten Staaten. Seine führenden Programme umfassen MZE829, einen oralen Kleinmolekül-Inhibitor von Apolipoprotein L1, der sich in Phase-II-Kliniktrial für die Behandlung von Patienten mit APOL1-Nierenkrankheit befindet, und MZE782, einen oralen Kleinmolekül-Inhibitor des Lösungsmitteltransporters SLC6A19, der sich in Phase-I-Kliniktrial für die Behandlung von chronischer Nierenkrankheit befindet. Maze Therapeutics, Inc. war zuvor als Modulus Therapeutics, Inc. bekannt und änderte seinen Namen im September 2018 zu Maze Therapeutics, Inc. Das Unternehmen wurde 2017 gegründet und hat seinen Sitz in South San Francisco, Kalifornien. KI
Unternehmen & Branche
| Name | Maze Therapeutics, Inc. |
|---|---|
| Ticker | MAZE |
| CIK | 0001842295 |
| Börse | Nasdaq |
| Sektor | Gesundheit |
| Industrie | Biotechnologie (Forschung) |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | 578784100 |
|---|---|
| ISIN | US5787841007 |
| Typ | Common Stock |
| Marktkapitalisierung | 1,41 Mrd. USD |
Sitz & Kontakt
| Sitz (Inkorporation) | DE |
|---|---|
| Geschäftsadresse | 171 OYSTER POINT BOULEVARD, SUITE 300, 94080 SOUTH SAN FRANCISCO, CA |
| Telefon | 6508505070 |
| EIN (IRS) | 00-0000000 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Emerging growth company |
Bewertung
| KBV (P/B) | 3,97 |
|---|---|
| FCF-Rendite | -8,0 % |
Qualität & Bilanz
| ROIC | -34,7 % |
|---|
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2024. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2024 | 2025 | TTM* | Verlauf |
|---|---|---|---|---|
| Bewertung | ||||
| KBV (P/B) | – | 5,76 | 4,13 | |
| FCF-Rendite | – | -5,5 % | -8,7 % | |
| Qualität & Bilanz | ||||
| ROIC | – | -34,7 % | -30,4 % | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
TTM* = letzte zwölf Monate (vorläufig, ungeprüft): jüngstes Geschäftsjahr + laufendes YTD − Vorjahres-YTD aus den Quartalsberichten (10-Q); Bewertungs-Multiples gegen die aktuelle Marktkapitalisierung. Kein testierter Jahresabschluss.
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
MAZE
Maze Therapeutics, Inc.
Effektiv
Risiko-Ausstieg
Handelsvolumen
Mittel
Insider
0,0
Keine Insider-Käufe
Institutionell
39,2
50 neu, 58 erhöht, -259534K $ netto
Aktivist
40,3
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 27.09 | +2.9 % vs SMA50 | |
| Kurs vs SMA200 | Bärisch | 15 % | 34.58 | -19.4 % vs SMA200 | |
| SMA-Cross | Bärisch | 10 % | DEATH | vor 47 Tagen @ 24.46 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 28.57 | EMA50: 28.44 | |
| MACD-Histogramm | Bärisch | 10 % | -0.337 | Bearisch | |
| RSI(14) | Neutral | 10 % | 47.4 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 22.2 | Neutral | |
| ADX(14)+DI | Neutral | 10 % | 19.4 | +DI: 21.5 / −DI: 18.1 | |
| Z-Score(60) | Neutral | 5 % | 0.39 | In Range | |
| 52W-Position | Neutral | 5 % | 38.1 % | Hoch 51.84 / Tief 13.14 | |
| Bollinger(20,2σ) | Neutral | 5 % | 24.0 % | Upper 33.05 / Mid 29.65 / Lower 26.25 | |
| LinReg-Slope(60) | Bullisch | 10 % | +0.0788 | R²=0.33 / annualisiert +73.7 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-07-01 | Coloma Jason V | Director, Officer, Chief Executive Officer | Open Market Sale | -30.311 | 29,95 | -907.920,54 | -321,7% | |
| 2026-07-01 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -13.409 | 29,87 | -400.459,79 | -141,9% | |
| 2026-07-01 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -1.200 | 30,34 | -36.404,28 | -12,9% | |
| 2026-07-01 | Coloma Jason V | Director, Officer, Chief Executive Officer | Open Market Sale | -2.593 | 29,98 | -77.726,21 | -27,5% | |
| 2026-07-01 | Coloma Jason V | Director, Officer, Chief Executive Officer | Open Market Sale | -1.597 | 30,44 | -48.606,13 | -17,2% | |
| 2026-06-29 | Dandekar Atul | Officer, CSBO | Open Market Sale | -7.500 | 28,02 | -210.150,00 | -74,5% | |
| 2026-06-23 | Coloma Jason V | Director, Officer, Chief Executive Officer | Open Market Sale | -23.865 | 26,05 | -621.673,70 | -220,3% | |
| 2026-06-22 | Coloma Jason V | Director, Officer, Chief Executive Officer | Open Market Sale | -2.040 | 26,00 | -53.040,00 | -18,8% | |
| 2026-06-22 | Coloma Jason V | Director, Officer, Chief Executive Officer | Open Market Sale | -1.953 | 26,00 | -50.780,93 | -18,0% | |
| 2026-06-01 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -1.600 | 26,36 | -42.172,16 | -14,9% | |
| 2026-06-01 | Coloma Jason V | Director, Officer, Chief Executive Officer | Open Market Sale | -6.090 | 26,20 | -159.536,69 | -56,5% | |
| 2026-06-01 | Coloma Jason V | Director, Officer, Chief Executive Officer | Open Market Sale | -553 | 26,24 | -14.511,38 | -5,1% | |
| 2026-06-01 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -13.253 | 25,57 | -338.940,17 | -120,1% | |
| 2026-05-29 | Dandekar Atul | Officer, CSBO | Open Market Sale | -7.500 | 26,34 | -197.553,75 | -70,0% | |
| 2026-05-26 | Coloma Jason V | Director, Officer, Chief Executive Officer | Open Market Sale | -25.582 | 26,02 | -665.515,73 | -235,8% | |
| 2026-05-22 | Coloma Jason V | Director, Officer, Chief Executive Officer | Open Market Sale | -4.504 | 26,00 | -117.104,45 | -41,5% | |
| 2026-05-22 | Coloma Jason V | Director, Officer, Chief Executive Officer | Open Market Sale | -2.478 | 26,00 | -64.428,00 | -22,8% | |
| 2026-05-15 | Coloma Jason V | Director, Officer, Chief Executive Officer | Open Market Sale | -1.822 | 26,00 | -47.372,00 | -16,8% | |
| 2026-05-15 | Coloma Jason V | Director, Officer, Chief Executive Officer | Open Market Sale | -116 | 26,00 | -3.016,00 | -1,1% | |
| 2026-05-14 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -15.000 | 26,22 | -393.354,00 | -139,4% | |
| 2026-04-29 | Dandekar Atul | Officer, CSBO | Open Market Sale | -7.500 | 25,37 | -190.299,00 | -67,4% | |
| 2026-04-01 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -3.348 | 30,06 | -100.635,86 | -35,7% | |
| 2026-04-01 | Bachrodt Amy | Officer, SVP, Finance | Open Market Sale | -2.200 | 29,32 | -64.509,94 | -22,9% | |
| 2026-04-01 | Bachrodt Amy | Officer, SVP, Finance | Open Market Sale | -300 | 30,34 | -9.101,01 | -3,2% | |
| 2026-04-01 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -11.352 | 29,24 | -331.948,37 | -117,6% | |
| 2026-04-01 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -300 | 31,07 | -9.320,01 | -3,3% | |
| 2026-03-30 | Dandekar Atul | Officer, CSBO | Open Market Sale | -6.710 | 29,26 | -196.305,08 | -69,6% | |
| 2026-03-30 | Dandekar Atul | Officer, CSBO | Open Market Sale | -790 | 30,02 | -23.713,67 | -8,4% | |
| 2026-03-20 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -5.044 | 50,02 | -252.293,82 | -89,4% | |
| 2026-03-20 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -6.161 | 48,20 | -296.976,83 | -105,2% | |
| 2026-03-20 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -3.795 | 49,32 | -187.168,64 | -66,3% | |
| 2026-03-10 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -29.652 | 50,45 | -1.495.807,00 | -530,0% | |
| 2026-03-10 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -348 | 51,02 | -17.753,22 | -6,3% | |
| 2026-03-02 | Bachrodt Amy | Officer, SVP, Finance | Open Market Sale | -1.300 | 44,44 | -57.773,82 | -20,5% | |
| 2026-03-02 | Bachrodt Amy | Officer, SVP, Finance | Open Market Sale | -3.700 | 45,47 | -168.236,78 | -59,6% | |
| 2026-02-27 | Dandekar Atul | Officer, CSBO | Open Market Sale | -3.739 | 45,13 | -168.756,03 | -59,8% | |
| 2026-02-27 | Dandekar Atul | Officer, CSBO | Open Market Sale | -3.761 | 45,72 | -171.967,21 | -60,9% | |
| 2026-02-02 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -5.936 | 46,37 | -275.271,32 | -97,5% | |
| 2026-02-02 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -600 | 44,21 | -26.523,00 | -9,4% | |
| 2026-02-02 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -100 | 47,23 | -4.723,00 | -1,7% | |
| 2026-02-02 | Bachrodt Amy | Officer, SVP, Finance | Open Market Sale | -4.064 | 46,03 | -187.067,95 | -66,3% | |
| 2026-02-02 | Bachrodt Amy | Officer, SVP, Finance | Open Market Sale | -200 | 44,15 | -8.830,00 | -3,1% | |
| 2026-02-02 | Bachrodt Amy | Officer, SVP, Finance | Open Market Sale | -736 | 46,63 | -34.321,37 | -12,2% | |
| 2026-02-02 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -8.364 | 45,89 | -383.816,43 | -136,0% | |
| 2026-01-29 | Dandekar Atul | Officer, CSBO | Open Market Sale | -2.800 | 45,01 | -126.022,40 | -44,7% | |
| 2026-01-29 | Dandekar Atul | Officer, CSBO | Open Market Sale | -3.500 | 44,04 | -154.146,65 | -54,6% | |
| 2026-01-29 | Dandekar Atul | Officer, CSBO | Open Market Sale | -1.200 | 43,18 | -51.821,28 | -18,4% | |
| 2026-01-22 | Bachrodt Amy | Officer, SVP, Finance | Open Market Sale | -5.000 | 45,52 | -227.612,00 | -80,7% | |
| 2026-01-07 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -25.156 | 40,20 | -1.011.298,87 | -358,4% | |
| 2026-01-07 | Sohn Catherine A. | Director | Open Market Sale | -26.920 | 39,11 | -1.052.784,67 | -373,1% | |
| 2026-01-06 | Sohn Catherine A. | Director | Open Market Sale | -2.493 | 38,62 | -96.269,69 | -34,1% | |
| 2026-01-05 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -412 | 40,00 | -16.480,00 | -5,8% | |
| 2026-01-02 | Bachrodt Amy | Officer, SVP, Finance | Open Market Sale | -2.595 | 39,57 | -102.681,30 | -36,4% | |
| 2026-01-02 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -4.432 | 40,43 | -179.187,53 | -63,5% | |
| 2026-01-02 | Bachrodt Amy | Officer, SVP, Finance | Open Market Sale | -2.405 | 38,70 | -93.072,30 | -33,0% | |
| 2025-12-30 | Dandekar Atul | Officer, CSBO | Open Market Sale | -100 | 40,36 | -4.036,00 | -1,4% | |
| 2025-12-30 | Bachrodt Amy | Officer, SVP, Finance | Open Market Sale | -5.000 | 40,08 | -200.407,00 | -71,0% | |
| 2025-12-29 | Dandekar Atul | Officer, CSBO | Open Market Sale | -6.035 | 41,13 | -248.211,10 | -88,0% | |
| 2025-12-29 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -27.800 | 40,34 | -1.121.424,20 | -397,4% | |
| 2025-12-29 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -17.200 | 40,93 | -703.930,64 | -249,4% | |
| 2025-12-29 | Bachrodt Amy | Officer, SVP, Finance | Open Market Sale | -9.400 | 40,54 | -381.071,30 | -135,0% | |
| 2025-12-29 | Bachrodt Amy | Officer, SVP, Finance | Open Market Sale | -600 | 41,16 | -24.694,98 | -8,8% | |
| 2025-12-29 | Dandekar Atul | Officer, CSBO | Open Market Sale | -66.365 | 40,51 | -2.688.552,33 | -952,7% | |
| 2025-09-15 | SCHELLER RICHARD H | Director | Open Market Sale | -20.744 | 22,37 | -464.034,98 | -164,4% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 4.567.274 | 0 | 4.567.274 | 136.333.129 | Neu | +100,0% | |
| TRV GP IV, LLC | 4.473.958 | 0 | 4.473.958 | 133.547.646 | Neu | +100,0% | |
| ARCH Venture Management, LLC | 4.120.053 | 0 | 4.120.053 | 122.983.582 | Neu | +100,0% | |
| Deep Track Capital, LP | 3.477.562 | 0 | 3.477.562 | 103.805.226 | Neu | +100,0% | |
| Janus Henderson Group Ltd. | 2.858.876 | 0 | 2.858.876 | 85.280.271 | Neu | +100,0% | |
| Paradigm Biocapital Advisors LP | 2.744.399 | 0 | 2.744.399 | 81.920.310 | Neu | +100,0% | |
| BlackRock, Inc. | 2.570.425 | 0 | 2.570.425 | 76.727.187 | Neu | +100,0% | |
| a16z Capital Management, L.L.C. | 1.702.225 | 0 | 1.702.225 | 50.811.416 | Neu | +100,0% | |
| Venrock Adviser, LLC | 1.602.034 | 0 | 1.602.034 | 47.820.715 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.435.656 | 0 | 1.435.656 | 42.854.332 | Neu | +100,0% | |
| Alphabet Inc. | 1.388.583 | 0 | 1.388.583 | 41.449.203 | Neu | +100,0% | |
| Logos Global Management LP | 1.235.000 | 0 | 1.235.000 | 36.864.750 | Neu | +100,0% | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.178.000 | 0 | 1.178.000 | 35.163.300 | Neu | +100,0% | |
| General Catalyst Group Management, LLC | 1.035.910 | 0 | 1.035.910 | 30.921.914 | Neu | +100,0% | |
| TRV GP V, LLC | 950.800 | 0 | 950.800 | 28.381.380 | Neu | +100,0% | |
| FMR LLC | 864.214 | 0 | 864.214 | 25.796.788 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 809.214 | 0 | 809.214 | 24.155.038 | Neu | +100,0% | |
| ArrowMark Colorado Holdings LLC | 767.383 | 0 | 767.383 | 22.906.383 | Neu | +100,0% | |
| Casdin Capital, LLC | 758.857 | 0 | 758.857 | 22.651.881 | Neu | +100,0% | |
| Cormorant Asset Management, LP | 750.000 | 0 | 750.000 | 22.387.500 | Neu | +100,0% | |
| Woodline Partners LP | 650.229 | 0 | 650.229 | 19.409.336 | Neu | +100,0% | |
| STATE STREET CORP | 636.722 | 0 | 636.722 | 19.006.152 | Neu | +100,0% | |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 636.162 | 0 | 636.162 | 18.989.436 | Neu | +100,0% | |
| Caligan Partners LP | 614.962 | 0 | 614.962 | 18.356.616 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 599.967 | 0 | 599.967 | 17.912.855 | Neu | +100,0% | |
| BALYASNY ASSET MANAGEMENT L.P. | 461.151 | 0 | 461.151 | 13.765.357 | Neu | +100,0% | |
| Ikarian Capital, LLC | 393.399 | 0 | 393.399 | 11.742.960 | Neu | +100,0% | |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 373.000 | 0 | 373.000 | 11.134.050 | Neu | +100,0% | |
| HHLR ADVISORS, LTD. | 366.028 | 0 | 366.028 | 10.925.936 | Neu | +100,0% | |
| MARSHALL WACE, LLP | 310.639 | 0 | 310.639 | 9.272.574 | Neu | +100,0% | |
| BOOTHBAY FUND MANAGEMENT, LLC | 284.476 | 0 | 284.476 | 8.491.609 | Neu | +100,0% | |
| WASHINGTON UNIVERSITY | 280.802 | 0 | 280.802 | 8.381.940 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 279.713 | 0 | 279.713 | 8.349.433 | Neu | +100,0% | |
| Candriam S.C.A. | 278.167 | 0 | 278.167 | 8.303.285 | Neu | +100,0% | |
| Mass General Brigham, Inc | 239.994 | 0 | 239.994 | 7.163.821 | Neu | +100,0% | |
| Freestone Grove Partners LP | 234.953 | 0 | 234.953 | 7.013.347 | Neu | +100,0% | |
| SPHERA FUNDS MANAGEMENT LTD. | 227.343 | 0 | 227.343 | 6.786.189 | Neu | +100,0% | |
| Aberdeen Group plc | 226.227 | 0 | 226.227 | 6.752.876 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 211.382 | 0 | 211.382 | 6.309.753 | Neu | +100,0% | |
| MORGAN STANLEY | 204.831 | 0 | 204.831 | 6.114.205 | Neu | +100,0% | |
| Spruce Street Capital LP | 200.000 | 0 | 200.000 | 5.970.000 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 195.084 | 0 | 195.084 | 5.823.258 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 186.433 | 0 | 186.433 | 5.565.025 | Neu | +100,0% | |
| Ensign Peak Advisors, Inc | 185.794 | 0 | 185.794 | 5.545.951 | Neu | +100,0% | |
| Foresite Capital Management IV, LLC | 156.901 | 0 | 156.901 | 4.683.495 | Neu | +100,0% | |
| Holocene Advisors, LP | 136.168 | 0 | 136.168 | 4.064.615 | Neu | +100,0% | |
| Qube Research & Technologies Ltd | 134.950 | 0 | 134.950 | 4.028.258 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 128.001 | 0 | 128.001 | 3.820.830 | Neu | +100,0% | |
| Atika Capital Management LLC | 111.500 | 0 | 111.500 | 3.328.276 | Neu | +100,0% | |
| AMERIPRISE FINANCIAL INC | 107.486 | 0 | 107.486 | 3.208.458 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| Y-Intercept (Hong Kong) Ltd | 14.370 | 21.728 | -33,9% | 428.801 | 27,62 | 100 % | 2 Q |
| China Universal Asset Management Co., Ltd. | 13.808 | 11.995 | +15,1% | 412.031 | 26,54 | 100 % | 4 Q |
| Police & Firemen's Retirement System of New Jersey | 10.407 | 7.101 | +46,6% | 310.545 | 20,00 | 100 % | 6 Q |
| Falcon Wealth Planning | 9.630 | 9.639 | -0,1% | 287.359 | 18,51 | 100 % | 3 Q |
| Mirae Asset Global Investments Co., Ltd. | 2.475 | 2.510 | -1,4% | 73.854 | 4,76 | 100 % | 3 Q |
| IFP Advisors, Inc | 328 | 8.988 | -96,4% | 9.788 | 0,63 | 100 % | 4 Q |
| Farther Finance Advisors, LLC | 326 | 359 | -9,2% | 9.512 | 0,61 | 0 % | 4 Q |
| Sterling Capital Management LLC | 222 | 829 | -73,2% | 6.624 | 0,43 | 0 % | 6 Q |
| GAMMA Investing LLC | 170 | 352 | -51,7% | 5.073 | 0,33 | 100 % | 5 Q |
| EverSource Wealth Advisors, LLC | 149 | 203 | -26,6% | 4.446 | 0,29 | 100 % | 5 Q |
| Torren Management, LLC | 112 | 112 | 0,0% | 3.342 | 0,22 | 0 % | 3 Q |
| SIGNATUREFD, LLC | 17 | 169 | -89,9% | 507 | 0,03 | 100 % | 3 Q |
| Fortitude Family Office, LLC | 11 | 0 | +100,0% | 328 | 0,02 | 100 % | 1 Q |
| SBI Securities Co., Ltd. | 6 | 6 | 0,0% | 179 | 0,01 | 100 % | 6 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 14 | 0,1 | 2 |
| 31.03.2026 | ✓ | 163 | 56,5 | 1.668 |
| 31.12.2025 | ✓ | 141 | 44,7 | 1.828 |
| 30.09.2025 | ✓ | 92 | 39,1 | 1.000 |
| 30.06.2025 | ✓ | 73 | 38,8 | 470 |
| 31.03.2025 | ✓ | 66 | 38,4 | 434 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| ARCH Venture Management, LLC | 4.120.053 | 122.983.582 |
| Paradigm Biocapital Advisors LP | 2.744.399 | 81.920.310 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.178.000 | 35.163.300 |
| Cormorant Asset Management, LP | 750.000 | 22.387.500 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 373.000 | 11.134.050 |
| Candriam S.C.A. | 278.167 | 8.303.285 |
| Aberdeen Group plc | 226.227 | 6.752.876 |
| Spruce Street Capital LP | 200.000 | 5.970.000 |
| Holocene Advisors, LP | 136.168 | 4.064.615 |
| Qube Research & Technologies Ltd | 134.950 | 4.028.258 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| CITADEL ADVISORS LLC | 775.714 | 327.497 | +73.1 % | 23.155.063 |
| Logos Global Management LP | 1.235.000 | 285.000 | +30.0 % | 36.864.750 |
| BlackRock, Inc. | 2.570.425 | 283.270 | +12.4 % | 76.727.187 |
| BALYASNY ASSET MANAGEMENT L.P. | 461.151 | 261.939 | +131.5 % | 13.765.357 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 636.162 | 258.147 | +68.3 % | 18.989.436 |
| BANK OF AMERICA CORP /DE/ | 195.084 | 176.703 | +961.3 % | 5.823.258 |
| GOLDMAN SACHS GROUP INC | 279.713 | 165.258 | +144.4 % | 8.349.433 |
| SPHERA FUNDS MANAGEMENT LTD. | 227.343 | 155.500 | +216.4 % | 6.786.189 |
| FMR LLC | 864.214 | 135.609 | +18.6 % | 25.796.788 |
| Freestone Grove Partners LP | 234.953 | 116.077 | +97.6 % | 7.013.347 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| Deep Track Capital, LP | 3.477.562 | -768.878 | -18.1 % | 103.805.226 |
| MARSHALL WACE, LLP | 310.639 | -536.833 | -63.3 % | 9.272.574 |
| Woodline Partners LP | 650.229 | -385.000 | -37.2 % | 19.409.336 |
| Foresite Capital Management IV, LLC | 156.901 | -365.756 | -70.0 % | 4.683.495 |
| Janus Henderson Group Ltd. | 2.858.876 | -283.711 | -9.0 % | 85.280.271 |
| Ikarian Capital, LLC | 378.999 | -265.681 | -41.2 % | 11.313.120 |
| Parkman Healthcare Partners LLC | 31.844 | -177.422 | -84.8 % | 950.543 |
| ADAR1 Capital Management, LLC | 50.095 | -129.437 | -72.1 % | 1.495.336 |
| BOOTHBAY FUND MANAGEMENT, LLC | 284.476 | -124.896 | -30.5 % | 8.491.609 |
| MILLENNIUM MANAGEMENT LLC | 29.892 | -124.578 | -80.6 % | 892.276 |
Zusätzlich aktuell von 88 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Δ-Balken |
|---|---|---|---|---|---|---|
| 15.05.2026 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 5,80 % | 2.858.876 | -1,50 pp | |
| 01.04.2026 | Paradigm BioCapital Advisors GP LLC (+2) | Passiv (13G) | 6,10 % | 3.051.087 | Neu | |
| 01.04.2026 | Paradigm BioCapital International Fund Ltd. | Passiv (13G) | 5,40 % | 2.688.520 | Neu | |
| 13.02.2026 | Frazier Life Sciences XI, L.P. (+2) | Passiv (13G/A) | 0,30 % | 149.026 | 0,00 pp | |
| 13.02.2026 | Frazier Life Sciences Public Fund, L.P. (+2) | Passiv (13G/A) | 9,00 % | 4.342.266 | +1,30 pp | |
| 13.02.2026 | Frazier Life Sciences X, L.P. (+4) | Passiv (13G/A) | 0,20 % | 75.982 | 0,00 pp | |
| 13.02.2026 | Frazier Life Sciences XII, L.P. (+2) | Passiv (13G/A) | Ausstieg | 0 | Neu | |
| 13.02.2026 | Third Rock Ventures GP IV, L.P. (+2) | Passiv (13G/A) | 9,30 % | 4.473.958 | -4,60 pp | |
| 13.02.2026 | Third Rock Ventures GP V, L.P. (+2) | Passiv (13G/A) | 2,00 % | 950.800 | -0,20 pp | |
| 06.02.2026 | GV 2023 GP, L.L.C. (+2) | Passiv (13G/A) | 1,30 % | 604.564 | -0,10 pp | |
| 06.02.2026 | Alphabet Holdings LLC (+2) | Passiv (13G/A) | 2,90 % | 1.388.583 | -2,60 pp | |
| 06.02.2026 | GV 2019 GP, L.L.C. (+2) | Passiv (13G/A) | 1,60 % | 784.019 | -2,50 pp | |
| 14.11.2025 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 7,30 % | 3.206.472 | +1,30 pp | |
| 14.11.2025 | Foresite Capital Management V, LLC (+1) | Passiv (13G/A) | 0,20 % | 86.291 | -0,60 pp | |
| 14.11.2025 | James Tananbaum | Passiv (13G/A) | 1,40 % | 608.948 | -4,20 pp | |
| 14.11.2025 | Foresite Capital Management IV, LLC (+1) | Passiv (13G/A) | 1,20 % | 522.657 | -3,60 pp | |
| 13.11.2025 | Matrix Capital Management Company, LP (+1) | Passiv (13G/A) | 3,50 % | 1.653.684 | -2,20 pp | |
| 14.08.2025 | Daniel Estes (+2) | Passiv (13G/A) | Ausstieg | 0 | Neu | |
| 14.08.2025 | Frazier Life Sciences Public Overage Fund, L.P. (+2) | Passiv (13G/A) | 2,30 % | 989.351 | +0,10 pp | |
| 14.08.2025 | Frazier Life Sciences Public Fund, L.P. (+2) | Passiv (13G/A) | 7,70 % | 3.352.915 | +0,20 pp | |
| 14.08.2025 | Frazier Life Sciences XI, L.P. (+2) | Passiv (13G/A) | 0,30 % | 149.026 | 0,00 pp | |
| 14.08.2025 | Frazier Life Sciences X, L.P. (+4) | Passiv (13G/A) | 0,20 % | 75.982 | 0,00 pp | |
| 14.08.2025 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 6,00 % | 2.625.089 | +0,30 pp | |
| 14.08.2025 | Deep Track Biotechnology Master Fund, Ltd. (+2) | Passiv (13G/A) | 9,02 % | 3.948.910 | +2,11 pp | |
| 15.05.2025 | ARCH Venture Partners X Overage, L.P. (+8) | Passiv (13G) | 9,40 % | 4.120.053 | Neu | |
| 14.05.2025 | JANUS HENDERSON GROUP PLC | Passiv (13G) | 5,70 % | 2.498.111 | Neu | |
| 14.05.2025 | Matrix Capital Management Company, LP (+1) | Passiv (13G) | 5,70 % | 2.486.184 | Neu | |
| 09.05.2025 | GV 2023 GP, L.L.C. (+2) | Passiv (13G) | 1,40 % | 604.564 | Neu | |
| 09.05.2025 | Alphabet Holdings LLC (+2) | Passiv (13G) | 5,50 % | 2.412.471 | Neu | |
| 09.05.2025 | GV 2019 GP, L.L.C. (+2) | Passiv (13G) | 4,10 % | 1.807.907 | Neu | |
| 09.05.2025 | Third Rock Ventures GP V, L.P. (+2) | Passiv (13G) | 2,20 % | 950.800 | Neu | |
| 09.05.2025 | Third Rock Ventures GP IV, L.P. (+2) | Passiv (13G) | 13,90 % | 6.073.958 | Neu | |
| 29.04.2025 | Frazier Life Sciences X, L.P. (+2) | Passiv (13G/A) | 0,20 % | 73.872 | 0,00 pp | |
| 29.04.2025 | Frazier Life Sciences Public Fund, L.P. (+2) | Passiv (13G/A) | 7,50 % | 3.272.062 | +0,50 pp | |
| 29.04.2025 | Frazier Life Sciences Public Overage Fund, L.P. (+2) | Passiv (13G/A) | 2,20 % | 965.503 | +0,10 pp | |
| 29.04.2025 | Frazier Life Sciences XI, L.P. (+3) | Passiv (13G/A) | 0,30 % | 139.902 | 0,00 pp | |
| 29.04.2025 | James Brush (+1) | Passiv (13G/A) | 9,70 % | 4.237.565 | +0,70 pp | |
| 29.04.2025 | Patrick J. Heron (+1) | Passiv (13G/A) | 10,20 % | 4.451.339 | +0,80 pp | |
| 29.04.2025 | Frazier Life Sciences Public Overage Fund, L.P. (+2) | Passiv (13G/A) | 2,10 % | 898.383 | +0,50 pp | |
| 29.04.2025 | Patrick J. Heron (+1) | Passiv (13G/A) | 9,40 % | 4.129.000 | +2,10 pp |
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 20.000.000 $ | -24.208.000 $ | -0,45 $ | 419.710.000 $ | 341.701.000 $ |
| 2025-12-31 | 10-K | 0 $ | -131.120.000 $ | -3,05 $ | 397.127.000 $ | 354.966.000 $ |
| 2025-09-30 | 10-Q | 0 $ | -30.087.000 $ | -0,66 $ | 422.058.000 $ | 379.436.000 $ |
| 2025-06-30 | 10-Q | 0 $ | -33.679.000 $ | -0,77 $ | 303.519.000 $ | 262.238.000 $ |
| 2025-03-31 | 10-Q | – | -32.786.000 $ | -1,15 $ | 332.840.000 $ | 292.068.000 $ |
| 2024-12-31 | 10-K | 167.500.000 $ | 52.231.000 $ | 1,25 $ | 240.542.000 $ | -311.183.000 $ |
| 2024-09-30 | 10-Q | 2.500.000 $ | -24.752.000 $ | -10,25 $ | – | – |
| 2024-06-30 | 10-Q | 165.000.000 $ | 139.056.000 $ | 3,22 $ | – | – |
| 2024-03-31 | 10-Q | – | -32.494.000 $ | -13,91 $ | – | – |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 12.05.2026 | 20,0 Mio. USD | -0,45 |
| Q3 2025 | 30.09.2025 | 06.11.2025 | – | -0,66 |
| Q2 2025 | 30.06.2025 | 12.08.2025 | 0 USD | -0,77 |
| Q1 2025 | 31.03.2025 | 14.05.2025 | – | -1,15 |
| Q3 2024 | 30.09.2024 | 06.11.2025 | 2,5 Mio. USD | -10,25 |
| Q2 2024 | 30.06.2024 | 12.08.2025 | 165,0 Mio. USD | 3,22 |
| Q1 2024 | 31.03.2024 | 14.05.2025 | – | -13,91 |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 12.05.2026 | 10-Q | 31.03.2026 | 42 Tage | SEC » |
| 25.03.2026 | 10-K | 31.12.2025 | 84 Tage | SEC » |
| 06.11.2025 | 10-Q | 30.09.2025 | 37 Tage | SEC » |
| 12.08.2025 | 10-Q | 30.06.2025 | 43 Tage | SEC » |
| 14.05.2025 | 10-Q | 31.03.2025 | 44 Tage | SEC » |
| 31.03.2025 | 10-K | 31.12.2024 | 90 Tage | SEC » |
Kapitalerhöhungen & Emissions-Historie
Emissions-Historie aus den finalen SEC-Prospekten: Börsengang (424B4) und Kapitalerhöhungen (424B5, Folge-/Sekundärplatzierungen). Volumen = Brutto-Erlös (bei Börsengängen zusätzlich der Ausgabepreis). Wiederholte Kapitalerhöhungen deuten auf Verwässerung der Altaktionäre hin.
| Datum (US) | Art | Volumen | |
|---|---|---|---|
| 22.04.2026 | Kapitalerhöhung | $150,2 Mio · $23,50/Aktie | SEC » |
| 31.01.2025 | Börsengang | $140,0 Mio · $16,00/Aktie | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Beträge in US-Dollar.
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | HV-Termin (US) | Stichtag (US) | Form | |
|---|---|---|---|---|---|
| 28.04.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 28.04.2026 | HV-Einladung | 08.06.2026 Jahres-HV | 13.04.2026 | DEF 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termin = Datum der Aktionärsversammlung, Stichtag (Record Date) = Nachweisstichtag für die Stimmberechtigung (aus dem Dokument extrahiert).
Kritische 8-K Meldungen ⓘ
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 25.03.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 02.09.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 12.05.2026 | Quartalszahlen | 0,10 | 65 | Maze Therapeutics gab am 12. Mai 2026 die Finanzzergebnisse für das erste Quartal 2026 bekannt. | SEC |
| 22.04.2026 | Wesentliche Vereinbarung | -0,20 | 70 | Maze Therapeutics unterzeichnete am 21. April 2026 ein Underwriting Agreement über die Emission von 5,54 Mio. Stammaktien und Pre-Funded War… 🔒 | SEC |
| 25.03.2026 | Personalwechsel | 0,20 | 40 | Maze Therapeutics ernennt Neil Kumar, CEO von BridgeBio Pharma, zum neuen Direktor (Klasse I) ab 27. März 2026. Die Ernennung bringt Biotech… 🔒 | SEC |
| 04.02.2026 | Finanzierung/Anleihe | 0,00 | 65 | Maze Therapeutics gab ein Material Definitive Agreement ein, das eine direkte finanzielle Verpflichtung begründet. Genaue Details sind in de… 🔒 | SEC |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-06-30 | 62.407 | 29,00 | 1.809.803 |
| 2026-06-29 | 14.463 | 28,43 | 411.183 |
| 2026-06-26 | 38 | 27,02 | 1.027 |
| 2026-06-24 | 1.086 | 26,41 | 28.681 |
| 2026-06-23 | 10.187 | 25,57 | 260.482 |
| 2026-06-22 | 6.432 | 25,68 | 165.174 |
| 2026-06-15 | 243 | 24,05 | 5.844 |
| 2026-06-12 | 2 | 24,09 | 48 |
| 2026-06-03 | 1.004 | 24,29 | 24.387 |
| 2026-06-02 | 1.911 | 25,46 | 48.654 |
| 2026-06-01 | 488 | 26,46 | 12.912 |
| 2026-05-27 | 847 | 26,35 | 22.318 |
| 2026-05-21 | 7.815 | 25,03 | 195.609 |
| 2026-05-18 | 910 | 25,56 | 23.260 |
| 2026-04-28 | 821 | 26,47 | 21.732 |
| 2026-04-20 | 357 | 28,09 | 10.028 |
| 2026-04-14 | 50.000 | 27,42 | 1.371.000 |
| 2026-04-09 | 250 | 28,09 | 7.023 |
| 2026-04-07 | 17 | 29,00 | 493 |
| 2026-04-01 | 71 | 29,85 | 2.119 |
| 2026-03-31 | 301 | 29,01 | 8.732 |
| 2026-03-27 | 56 | 31,71 | 1.776 |
| 2026-03-25 | 10.522 | 49,00 | 515.578 |
| 2026-03-24 | 7.646 | 49,00 | 374.654 |
| 2026-03-23 | 1.418 | 48,03 | 68.107 |
| 2026-03-20 | 20.307 | 49,43 | 1.003.775 |
| 2026-03-19 | 4.506 | 48,47 | 218.406 |
| 2026-03-11 | 1.954 | 51,06 | 99.771 |
| 2026-03-06 | 44.221 | 45,30 | 2.003.211 |
| 2026-03-05 | 39.742 | 46,48 | 1.847.208 |
| 2026-03-03 | 29.983 | 45,61 | 1.367.525 |
| 2026-02-26 | 371 | 47,23 | 17.522 |
| 2026-02-20 | 45 | 45,04 | 2.027 |
| 2026-02-13 | 2.366 | 47,04 | 111.297 |
| 2026-02-12 | 33.369 | 47,22 | 1.575.684 |
| 2026-02-11 | 4.379 | 48,37 | 211.812 |
| 2026-02-10 | 6.217 | 47,71 | 296.613 |
| 2026-02-06 | 27.413 | 43,95 | 1.204.801 |
| 2026-02-05 | 559 | 48,14 | 26.910 |
| 2026-02-02 | 310 | 43,58 | 13.510 |
| 2026-01-30 | 1.251 | 45,00 | 56.295 |
| 2026-01-29 | 364 | 43,36 | 15.783 |